Global Big Pharma's M&A Race for In Vivo CAR-T Platforms

Global pharmaceutical giants are actively pursuing mergers and acquisitions (M&A) to secure in vivo CAR-T platform technologies, aiming to overcome the limitations of ex vivo approaches. AstraZeneca, for instance, acquired Belgian biotech EsoBiotec for up to $1 billion, while Kite, a subsidiary of Gilead Sciences, made a surprise acquisition of Interius BioTherapeutics for $350 million. These moves are seen as strategic efforts to lead the next-generation platform that bypasses the costly and complex cell extraction and cultivation process by reprogramming immune cells directly within the patient's body. The intent is to preemptively mitigate the risk of astronomical cost increases during later-stage licensing by securing early-stage platforms.

EsoBiotec's ENaBL Platform and Clinical Value Assessment

The core technology acquired by AstraZeneca from EsoBiotec is the 'ENaBL' platform, which is based on nanobodies and utilizes an immune-shielded lentiviral vector. The platform's lead candidate, 'ESO-T01,' targets B-cell maturation antigen (BCMA) in multiple myeloma patients and reprograms T cells directly in vivo. According to a 2026 clinical Phase 1 trial published in Nature Medicine, four out of five treated patients showed objective responses, with three achieving complete remission, demonstrating strong efficacy. Despite adverse effects such as high-grade cytokine release syndrome (CRS) and a history of early clinical hold, AstraZeneca has boldly invested in the technology, confident in its potential.

Kite's Portfolio Diversification through Interius Acquisition

Kite, which already holds the ex vivo CAR-T therapy Yescarta, is accelerating its position in the next-generation market by integrating Interius' in vivo CAR-T and NK cell platform. Interius' lead pipeline, 'INT2104,' employs an innovative mechanism that targets CD7-positive T cells and NK cells to generate CAR cells that attack CD20-positive B cells in vivo. This technology, now in Phase 1 clinical trials, eliminates the need for pre-treatment lymphodepletion chemotherapy, significantly reducing the physical burden on patients. Big pharma's early bets on these platforms reflect a deep understanding of the cell therapy market's exponential value growth during later-stage clinical development.

Market Shifts from Early Platform Securing

The aggressive acquisition of early-stage gene delivery and editing technologies by global big pharma, despite technical uncertainties, is expected to completely reshape the biotech industry landscape. Given the platform's versatility across various cancers and autoimmune diseases, its value at the negotiation table grows exponentially as data accumulates. As a result, biotech startups with gene therapy delivery capabilities are being revalued in the market, opening up active licensing and strategic exit opportunities. Ultimately, the prevailing view is that early investment with risk is more cost-effective than purchasing mature technologies at a later, higher price.